

TDMS No. 99023 - 04

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Date Report Reqsted: 07/26/2007

Test Type: CHRONIC

beta-Myrcene

Time Report Reqsted: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

F1_M3

C Number: C99023

Lock Date: 12/22/2004

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include ALL

TDMSE Version: 1.8.0

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Dosing Accident				3
Moribund Sacrifice	7	6	8	12
Natural Death	8	9	11	14
Survivors				
Natural Death	1			
Terminal Sacrifice	34	35	31	21
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(49)
Gallbladder	(49)	(49)	(49)	(49)
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				1 (2%)
Intestine Large, Cecum	(49)	(48)	(49)	(47)
Intestine Small, Duodenum	(49)	(47)	(47)	(48)
Adenoma		1 (2%)		
Intestine Small, Ileum	(49)	(47)	(47)	(47)
Carcinoma		1 (2%)		
Intestine Small, Jejunum	(49)	(47)	(49)	(45)
Liver	(50)	(50)	(50)	(50)
Hemangiosarcoma	5 (10%)	1 (2%)	1 (2%)	
Hemangiosarcoma, Metastatic, Spleen	1 (2%)			
Hemangiosarcoma, Multiple		2 (4%)	1 (2%)	
Hepatoblastoma	4 (8%)	6 (12%)	11 (22%)	1 (2%)
Hepatocellular Adenoma	11 (22%)	10 (20%)	13 (26%)	8 (16%)
Hepatocellular Adenoma, Multiple	15 (30%)	31 (62%)	30 (60%)	10 (20%)
Hepatocellular Carcinoma	13 (26%)	16 (32%)	19 (38%)	9 (18%)
Hepatocellular Carcinoma, Multiple	1 (2%)	4 (8%)	9 (18%)	1 (2%)
Ito Cell Tumor Malignant	2 (4%)			
Mesentery	(4)	(7)	(5)	(3)
Hepatoblastoma, Metastatic, Liver		1 (14%)		
Hepatocellular Carcinoma, Metastatic, Liver			1 (20%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				1 (33%)
Pancreas	(50)	(50)	(50)	(50)
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(49)	(50)
Squamous Cell Carcinoma			1 (2%)	1 (2%)
Squamous Cell Papilloma		2 (4%)	1 (2%)	
Stomach, Glandular	(50)	(50)	(50)	(50)
Tongue	(1)	(0)	(0)	(0)
Squamous Cell Carcinoma	1 (100%)			
Tooth	(38)	(33)	(35)	(13)
Peridental Tissue, Fibrosarcoma		1 (3%)		
CARDIOVASCULAR SYSTEM				
Blood Vessel	(0)	(2)	(1)	(2)
Heart	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver			1 (2%)	
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				1 (2%)
Subcapsular, Adenoma	2 (4%)	4 (8%)		
Adrenal Medulla	(50)	(50)	(50)	(50)
Pheochromocytoma Benign			1 (2%)	
Pheochromocytoma Malignant		1 (2%)		
Islets, Pancreatic	(50)	(50)	(50)	(50)
Adenoma		1 (2%)		
Pituitary Gland	(49)	(49)	(50)	(49)
Pars Intermedia, Adenoma			1 (2%)	
Thyroid Gland	(50)	(50)	(50)	(50)
Follicular Cell, Adenoma		1 (2%)	1 (2%)	
Follicular Cell, Carcinoma	1 (2%)		1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Epididymis	(50)	(50)	(50)	(50)
Hepatoblastoma, Metastatic, Liver		1 (2%)		
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				1 (2%)
Preputial Gland	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)			
Prostate	(50)	(50)	(50)	(50)
Seminal Vesicle	(50)	(50)	(50)	(50)
Hepatoblastoma, Metastatic, Liver		1 (2%)		
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				1 (2%)
Testes	(50)	(50)	(50)	(50)
Interstitial Cell, Adenoma		1 (2%)	1 (2%)	
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Hemangiosarcoma		1 (2%)		
Hemangiosarcoma, Metastatic, Spleen	1 (2%)			
Lymph Node	(2)	(0)	(5)	(1)
Bronchial, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (50%)			
Bronchial, Hepatocellular Carcinoma, Metastatic, Liver			1 (20%)	
Bronchial, Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				1 (100%)
Mediastinal, Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				1 (100%)
Lymph Node, Mandibular	(49)	(50)	(48)	(49)
Melanoma Malignant, Metastatic, Eye			1 (2%)	
Lymph Node, Mesenteric	(49)	(50)	(47)	(44)
Hepatoblastoma, Metastatic, Liver		1 (2%)		
Pheochromocytoma Malignant,		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Metastatic, Adrenal Medulla				
Spleen	(49)	(50)	(48)	(49)
Hemangiosarcoma	1 (2%)	2 (4%)	2 (4%)	
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				1 (2%)
Thymus	(47)	(47)	(48)	(47)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Hepatoblastoma, Metastatic, Liver		1 (2%)		
Hepatocellular Carcinoma, Metastatic, Liver			1 (2%)	
INTEGUMENTARY SYSTEM				
Skin	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)			
Squamous Cell Carcinoma			1 (2%)	
Subcutaneous Tissue, Sarcoma	1 (2%)			
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Chondroma		1 (2%)		
Skeletal Muscle	(0)	(2)	(1)	(1)
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Peripheral Nerve	(0)	(0)	(1)	(0)
Spinal Cord	(0)	(0)	(1)	(0)
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	5 (10%)	9 (18%)	6 (12%)	13 (26%)
Alveolar/Bronchiolar Adenoma, Multiple	3 (6%)	4 (8%)	3 (6%)	1 (2%)
Alveolar/Bronchiolar Carcinoma	5 (10%)	5 (10%)	2 (4%)	2 (4%)
Alveolar/Bronchiolar Carcinoma,	1 (2%)	2 (4%)	1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Metastatic, Lung				
Carcinoma, Metastatic, Harderian Gland			1 (2%)	
Carcinoma, Metastatic, Thyroid Gland	1 (2%)		1 (2%)	
Hepatoblastoma, Metastatic, Liver		1 (2%)		
Hepatocellular Carcinoma, Metastatic, Liver	4 (8%)	8 (16%)	10 (20%)	5 (10%)
Melanoma Malignant, Metastatic, Eye			1 (2%)	
Mediastinum, Hemangiosarcoma			1 (2%)	
Nose	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Harderian Gland			1 (2%)	
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(50)
Melanoma Malignant			1 (2%)	
Harderian Gland	(50)	(50)	(50)	(50)
Adenoma	8 (16%)	8 (16%)	10 (20%)	6 (12%)
Adenoma, Multiple	1 (2%)			
Carcinoma	1 (2%)	2 (4%)	2 (4%)	1 (2%)
Bilateral, Adenoma		2 (4%)		
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Hepatocellular Carcinoma, Metastatic, Liver			2 (4%)	
Renal Tubule, Adenoma	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Urinary Bladder	(50)	(50)	(49)	(49)
SYSTEMIC LESIONS				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma		1 (2%)	3 (6%)	
Lymphoma Malignant	1 (2%)	1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Tumor Summary for Males				
Total Animals with Primary Neoplasms (b)	43	49	50	29
Total Primary Neoplasms	84	120	123	54
Total Animals with Benign Neoplasms	33	45	44	24
Total Benign Neoplasms	46	76	68	39
Total Animals with Malignant Neoplasms	30	33	41	13
Total Malignant Neoplasms	38	44	55	15
Total Animals with Metastatic Neoplasms	7	12	14	6
Total Metastatic Neoplasms	9	17	22	16
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Dosing Accident		1	1	
Moribund Sacrifice	4	5	6	5
Natural Death	7	10	8	28
Survivors				
Terminal Sacrifice	39	34	35	17
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Esophagus	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Uterus			1 (2%)	
Nerve, Schwannoma Malignant, Metastatic, Uncertain Primary Site		1 (2%)		
Gallbladder	(47)	(50)	(50)	(49)
Sarcoma, Metastatic, Skin		1 (2%)		
Intestine Large, Cecum	(49)	(50)	(50)	(47)
Intestine Large, Colon	(50)	(50)	(50)	(47)
Intestine Large, Rectum	(50)	(49)	(50)	(49)
Intestine Small, Jejunum	(50)	(48)	(49)	(40)
Carcinoma	1 (2%)			
Sarcoma, Metastatic, Skin			1 (2%)	
Liver	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Uterus			1 (2%)	
Hemangiosarcoma			1 (2%)	
Hemangiosarcoma, Metastatic, Skin	1 (2%)			
Hepatocellular Adenoma	6 (12%)	11 (22%)	6 (12%)	7 (14%)
Hepatocellular Adenoma, Multiple		2 (4%)		
Hepatocellular Carcinoma	1 (2%)	7 (14%)	2 (4%)	1 (2%)
Sarcoma, Metastatic, Skin		1 (2%)		
Mesentery	(15)	(18)	(3)	(0)
Hemangioma	1 (7%)			
Hepatocellular Carcinoma, Metastatic, Liver		1 (6%)		
Sarcoma, Metastatic, Skin		1 (6%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Schwannoma Malignant, Metastatic, Uncertain Primary Site		1 (6%)		
Pancreas	(50)	(49)	(50)	(48)
Sarcoma, Metastatic, Skin			1 (2%)	
Schwannoma Malignant, Metastatic, Uncertain Primary Site		1 (2%)		
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(49)	(50)	(47)
Carcinoma, Metastatic, Uterus			1 (2%)	
Squamous Cell Papilloma	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Serosa, Schwannoma Malignant, Metastatic, Uncertain Primary Site		1 (2%)		
Stomach, Glandular	(50)	(50)	(50)	(49)
Tooth	(1)	(3)	(4)	(0)
CARDIOVASCULAR SYSTEM				
Blood Vessel	(2)	(2)	(2)	(1)
Heart	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Uterus			1 (2%)	
Hemangioma			1 (2%)	
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Sarcoma, Metastatic, Skin		1 (2%)		
Subcapsular, Adenoma	1 (2%)			
Adrenal Medulla	(50)	(50)	(50)	(50)
Hepatocellular Carcinoma, Metastatic, Liver		1 (2%)		
Parathyroid Gland	(47)	(34)	(43)	(44)
Pituitary Gland	(50)	(50)	(50)	(50)
Pars Distalis, Adenoma	1 (2%)	1 (2%)	1 (2%)	
Thyroid Gland	(50)	(50)	(50)	(50)
Follicular Cell, Adenoma	1 (2%)		1 (2%)	
GENERAL BODY SYSTEM				
None				

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
GENITAL SYSTEM				
Clitoral Gland	(49)	(48)	(50)	(49)
Hemangiosarcoma		1 (2%)		
Ovary	(50)	(50)	(49)	(49)
Carcinoma, Metastatic, Uterus			1 (2%)	
Cystadenoma	2 (4%)	1 (2%)		
Granulosa-Theca Tumor Benign				1 (2%)
Luteoma	1 (2%)		1 (2%)	
Oviduct	(0)	(0)	(1)	(0)
Uterus	(50)	(50)	(50)	(50)
Hemangiosarcoma		1 (2%)		
Polyp Stromal		1 (2%)	1 (2%)	1 (2%)
Endometrium, Carcinoma			1 (2%)	
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(49)	(49)	(50)
Hemangiosarcoma		1 (2%)		
Hemangiosarcoma, Metastatic, Skin	1 (2%)			
Sarcoma, Metastatic, Skin		1 (2%)		
Lymph Node	(7)	(8)	(7)	(0)
Bronchial, Alveolar/Bronchiolar		1 (13%)		
Carcinoma, Metastatic, Lung				
Bronchial, Sarcoma, Metastatic, Skin		1 (13%)		
Mediastinal, Alveolar/Bronchiolar		1 (13%)		
Carcinoma, Metastatic, Lung				
Mediastinal, Carcinoma, Metastatic,			1 (14%)	
Uterus				
Mediastinal, Fibrosarcoma, Metastatic,			1 (14%)	
Skin				
Mediastinal, Hepatocellular Carcinoma,		1 (13%)		
Metastatic, Liver				
Mediastinal, Sarcoma, Metastatic, Skin		1 (13%)		
Pancreatic, Carcinoma, Metastatic,			1 (14%)	
Uterus				
Lymph Node, Mandibular	(50)	(50)	(49)	(49)
Lymph Node, Mesenteric	(47)	(48)	(44)	(39)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Sarcoma, Metastatic, Skin		1 (2%)		
Spleen	(49)	(50)	(50)	(50)
Hemangiosarcoma, Metastatic, Skin	1 (2%)			
Thymus	(49)	(48)	(47)	(48)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)		
Hemangioma			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver		1 (2%)		
Sarcoma, Metastatic, Skin		2 (4%)		
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(50)
Skin	(50)	(50)	(50)	(50)
Basosquamous Tumor Benign	1 (2%)			
Subcutaneous Tissue, Fibroma	1 (2%)			
Subcutaneous Tissue, Fibrosarcoma	1 (2%)		1 (2%)	1 (2%)
Subcutaneous Tissue, Hemangioma	1 (2%)			
Subcutaneous Tissue, Hemangiosarcoma	1 (2%)			
Subcutaneous Tissue, Sarcoma	1 (2%)	4 (8%)	1 (2%)	
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Skeletal Muscle	(0)	(3)	(0)	(0)
Sarcoma, Metastatic, Skin		1 (33%)		
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Peripheral Nerve	(0)	(1)	(0)	(0)
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	4 (8%)	1 (2%)	5 (10%)	3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Alveolar/Bronchiolar Adenoma, Multiple				2 (4%)
Alveolar/Bronchiolar Carcinoma	2 (4%)	1 (2%)	1 (2%)	
Carcinoma, Metastatic, Uterus			1 (2%)	
Fibrosarcoma, Metastatic, Skin			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver		2 (4%)	1 (2%)	
Sarcoma, Metastatic, Skin		2 (4%)		
Sarcoma, Metastatic, Uncertain Primary Site		1 (2%)		
Mediastinum, Fibrosarcoma, Metastatic, Skin			1 (2%)	
Nose	(50)	(50)	(50)	(50)
Trachea	(50)	(50)	(50)	(50)
SPECIAL SENSES SYSTEM				
Ear	(0)	(0)	(1)	(0)
Eye	(50)	(50)	(50)	(49)
Harderian Gland	(50)	(50)	(50)	(49)
Adenoma	4 (8%)	6 (12%)	5 (10%)	5 (10%)
Carcinoma			1 (2%)	
Bilateral, Adenoma		1 (2%)		
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Uterus			1 (2%)	
Ureter	(0)	(0)	(1)	(0)
Urinary Bladder	(50)	(50)	(50)	(49)
Carcinoma, Metastatic, Uterus			1 (2%)	
SYSTEMIC LESIONS				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma			2 (4%)	1 (2%)
Lymphoma Malignant	7 (14%)	6 (12%)	3 (6%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
--------------------	--------	-----------	----------	----------

Tumor Summary for Females

Total Animals with Primary Neoplasms (b)	30	28	27	21
Total Primary Neoplasms	39	46	36	24
Total Animals with Benign Neoplasms	21	19	20	18
Total Benign Neoplasms	25	25	23	20
Total Animals with Malignant Neoplasms	14	18	12	4
Total Malignant Neoplasms	14	21	13	4
Total Animals with Metastatic Neoplasms	1	7	4	
Total Metastatic Neoplasms	3	27	16	
Total Animals with Malignant Neoplasms Uncertain Primary Site		2		
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors